<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927663</url>
  </required_header>
  <id_info>
    <org_study_id>20926</org_study_id>
    <secondary_id>NCI-2021-04300</secondary_id>
    <secondary_id>5R01MH115043-03</secondary_id>
    <nct_id>NCT04927663</nct_id>
  </id_info>
  <brief_title>11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>A First-in-Human, Phase I PET Imaging Study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Evans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research Acquisition Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can&#xD;
      be useful for detecting certain cell receptor expression in tumor cells in patients with&#xD;
      prostate cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a&#xD;
      small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that&#xD;
      they show up better on the PET scan. Anti-hormone therapy (including enzalutamide) can cause&#xD;
      more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells&#xD;
      resist hormone therapies. If researchers can find a better way to detect whether&#xD;
      glucocorticoid receptors are increasing during therapy, it may lead to more successful&#xD;
      therapies using glucocorticoid receptor antagonists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility of metastatic lesion detection in&#xD;
      enzalutamide/apalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC)&#xD;
      using 11C-YJH08 PET. (Cohort A) II. To determine the mean percent change from baseline at the&#xD;
      time of progression on enzalutamide or apalutamide in standardized uptake value (SUV)max-ave&#xD;
      on paired 11C-YJH08 PET on a per-patient and per-lesion basis. (Cohort B)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and determine average organ uptake of 11C-YJH08. (Cohort A and B)&#xD;
      II. To descriptively report the patterns of intra-tumoral uptake of 11C-YJH08 on whole body&#xD;
      PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient&#xD;
      heterogeneity, and tumor-to-background signal. (Cohort A and B) III. To determine whether&#xD;
      baseline uptake on 11C-YJH08 PET is associated with subsequent clinical outcomes including&#xD;
      objective response rate, progression-free survival, and prostate specific antigen (PSA50)&#xD;
      response. (Cohort B)&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To determine the association between uptake on 11C-YJH08 PET with glucocorticoid receptor&#xD;
      (GR) expression and transcriptional signature scores on paired metastatic tumor biopsies.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive 11C-YJH08 intravenously (IV) over 1-2 minutes and 10-60 minutes&#xD;
      later, undergo either PET/magnetic resonance imaging (MRI) or PET/computed tomography (CT)&#xD;
      over 90 minutes at baseline.&#xD;
&#xD;
      ARM II: Patients receive 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo&#xD;
      either PET/MRI or PET/CT over 90 minutes at baseline and at time of disease progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed up on day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of 11C-YJH08 PET in metastatic lesion detection (Cohort A only)</measure>
    <time_frame>Up to day 1 follow-up</time_frame>
    <description>Will be descriptively reported on a lesion-per-lesion basis, using as reference standard staging scans including computed tomography or magnetic resonance imaging of the chest/abdomen/pelvis and whole body bone scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from baseline at the time of progression in standardized uptake value (SUV)max-ave on paired 11C-YJH08 PET per-patient basis (Cohort B only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be descriptively reported along with range on a per-patient basis. Wilcoxon signed rank test will be used to compare the follow up to baseline PET scan values at patient level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from baseline at the time of progression in standardized uptake value (SUV)max-ave on paired 11C-YJH08 PET per-lesion (Cohort B only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be descriptively reported along with range on a per-lesion basis. Wilcoxon signed rank test will be used to compare the follow up to baseline PET scan values at lesion level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to day 1 follow-up</time_frame>
    <description>As recorded by Common Terminology Criteria for Adverse Events Version 5.0 criteria and organ dosimetry of 11C-YJH08 PET. Will be descriptively reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive patterns of intra-tumoral uptake of 11C-YJH08 on whole body PET</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Including by site of disease, uptake by tumor type, inter-tumoral and interpatient heterogeneity, and tumor-to-background signal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between baseline uptake on 11C-YJH08 PET and objective response rate (Cohort B only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be compared between dichotomized groups using the chi-squared test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between baseline uptake on 11C-YJH08 PET with progression-free survival (Cohort B only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The log rank test will be used to compare progression-free survival between dichotomized subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between baseline uptake on 11C-YJH08 PET with prostate specific antigen (PSA50) response (Cohort B only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be compared between dichotomized groups using the chi-squared test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer AJCC v8</condition>
  <condition>Stage IVA Prostate Cancer AJCC v8</condition>
  <condition>Stage IVB Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Cohort A: 11C-YJH08 with PET/MRI or PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive approximately 20 millicurie (mCi) of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and at time of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo CT imaging</description>
    <arm_group_label>Cohort A: 11C-YJH08 with PET/MRI or PET/CT</arm_group_label>
    <arm_group_label>Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Cohort A: 11C-YJH08 with PET/MRI or PET/CT</arm_group_label>
    <arm_group_label>Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET imaging</description>
    <arm_group_label>Cohort A: 11C-YJH08 with PET/MRI or PET/CT</arm_group_label>
    <arm_group_label>Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-YJH08</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A: 11C-YJH08 with PET/MRI or PET/CT</arm_group_label>
    <arm_group_label>Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression</arm_group_label>
    <other_name>Radioactive Tag</other_name>
    <other_name>Radioactive Tracer</other_name>
    <other_name>Radioactive Label</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COHORT A: Histologically-confirmed progressive metastatic castration resistant&#xD;
             prostate cancer with evidence of progression by the Prostate Cancer Clinical Trials&#xD;
             Working Group 3 (PCWG3) on current enzalutamide or apalutamide treatment at the time&#xD;
             of study entry&#xD;
&#xD;
          -  COHORT B: Metastatic castration-resistant prostate cancer with planned treatment with&#xD;
             enzalutamide or apalutamide as next line of systemic therapy at the time of study&#xD;
             entry. Patients must not have received first dose of enzalutamide or apalutamide prior&#xD;
             to baseline 11C-YJH08 PET&#xD;
&#xD;
          -  Patients in Cohort A and B must have serum testosterone level &lt; 50 ng/dL and must&#xD;
             remain on luteinizing hormone-releasing hormone (LHRH) analog therapy for the duration&#xD;
             of study participation, in the absence of prior bilateral orchiectomy&#xD;
&#xD;
          -  The subject is able and willing to comply with study procedures and provide signed and&#xD;
             dated informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Age 18 years or older at the time of study entry&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN) OR estimated creatinine&#xD;
             clearance &gt; 50 ml/min&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt;= 50,000/microliter&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1000/microliter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who because of age, general medical or psychiatric condition, or physiologic&#xD;
             status cannot give valid informed consent&#xD;
&#xD;
          -  Concurrent treatment with any dose of systemic glucocorticoids within 7 days prior to&#xD;
             cycle 1 day 1 (C1D1)&#xD;
&#xD;
          -  History of adrenal insufficiency requiring use of systemic glucocorticoid replacement&#xD;
&#xD;
          -  History of Cushing's disease or Cushing's syndrome&#xD;
&#xD;
          -  Any condition that, in the opinion of the principal investigator, would impair the&#xD;
             patient's ability to comply with study procedures&#xD;
&#xD;
          -  Contra-indication to MRI (e.g. pacemaker placement, severe claustrophobia) (applicable&#xD;
             only for patients scheduled for PET/MRI)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Evans, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khadija Siddiqua</last_name>
    <phone>(310) 794-7329</phone>
    <email>khadija.siddiqua@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khadija Siddiqua</last_name>
      <phone>310-794-7329</phone>
      <email>khadija.siddiqua@ucsf.edu</email>
    </contact>
    <contact_backup>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Evans, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael Evans</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

